Australia markets close in 1 hour 42 minutes

Beximco Pharmaceuticals Limited (BXP.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
36.500.00 (0.00%)
At close: 12:33PM BST
Currency in GBp

Valuation measures4

Market cap (intra-day) 384.39M
Enterprise value 429.59M
Trailing P/E 4.59
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.54
Price/book (mrq)0.50
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.06

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3-13.10%
S&P500 52-week change 321.61%
52-week high 345.00
52-week low 30.00
50-day moving average 338.96
200-day moving average 338.98

Share statistics

Avg vol (3-month) 348.01k
Avg vol (10-day) 349.45k
Shares outstanding 5446.11M
Implied shares outstanding 61.05B
Float 8297.32M
% held by insiders 10.00%
% held by institutions 11.61%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.03
Forward annual dividend yield 46.89%
Trailing annual dividend rate 33.50
Trailing annual dividend yield 39.59%
5-year average dividend yield 43.69
Payout ratio 432.26%
Dividend date 3N/A
Ex-dividend date 410 Nov 2023
Last split factor 2110:100
Last split date 323 Nov 2020

Financial highlights

Currency in BDT.

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 11.80%
Operating margin (ttm)19.59%

Management effectiveness

Return on assets (ttm)6.55%
Return on equity (ttm)10.29%

Income statement

Revenue (ttm)41.65B
Revenue per share (ttm)93.37
Quarterly revenue growth (yoy)10.20%
Gross profit (ttm)N/A
EBITDA 9.04B
Net income avi to common (ttm)4.92B
Diluted EPS (ttm)0.08
Quarterly earnings growth (yoy)15.90%

Balance sheet

Total cash (mrq)1.73B
Total cash per share (mrq)3.88
Total debt (mrq)7.6B
Total debt/equity (mrq)15.50%
Current ratio (mrq)1.63
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)8.18B
Levered free cash flow (ttm)4.27B